Kiadis Submits Response to the European Medicines Agency’s Day 180 Second List of Outstanding Issues

Amsterdam, The Netherlands, May 22, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted a response to the European Medicines Agency’s (EMA) second Day 180 list of outstanding issues for ATIR101. Kiadis submitted a marketing authorization application (MAA) to the EMA in 2017 seeking approval of ATIR101 as an adjunctive immunotherapy for hematopoietic stem cell transplant (HSCT) in adults with late-stage blood cancer.

The second Day 180 List of Issues was focused on one remaining major observation. In drafting the company’s response, Kiadis has thoroughly analyzed this observation and have created multiple analyses of existing clinical data to address this observation, including analyses of various (pooled) ATIR and historical control data.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...